NO313672B1 - N-(3-benzofuranyl)urea-derivater, farmasöytiske sammensetninger og anvendelse derav, samt fremgangsmåte - Google Patents

N-(3-benzofuranyl)urea-derivater, farmasöytiske sammensetninger og anvendelse derav, samt fremgangsmåte Download PDF

Info

Publication number: NO313672B1
Authority: NO; Norway
Prior art keywords: carbon atoms; chain; straight; stands; alkoxycarbonyl
Prior art date: 1995-03-06

Application number

NO19960884A

Other languages

English (en)

Norwegian (no)

Other versions

NO960884L (no

NO960884D0 (no

Inventor

Gabriele Braeunlich

Ruediger Fischer

Mazen Es-Sayed

Rolf Henning

Michael Sperzel

Karl-Heinz Schlemmer

Ulrich Nielsch

Stephen Tudhope

Graham Sturton

Trevor S Abram

Mary F Fitzgerald

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-06

Filing date

1996-03-05

Publication date

2002-11-11

1996-03-05 Application filed by Bayer Ag filed Critical Bayer Ag

1996-03-05 Publication of NO960884D0 publication Critical patent/NO960884D0/no

1996-09-09 Publication of NO960884L publication Critical patent/NO960884L/no

2002-11-11 Publication of NO313672B1 publication Critical patent/NO313672B1/no

Links

LRSNVYGRZAFKQZ-UHFFFAOYSA-N 1-benzofuran-3-ylurea Chemical class C1=CC=C2C(NC(=O)N)=COC2=C1 LRSNVYGRZAFKQZ-UHFFFAOYSA-N 0.000 title claims description 18
238000000034 method Methods 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 3
230000008569 process Effects 0.000 title claims 2
125000004432 carbon atom Chemical group C* 0.000 claims description 135
125000000217 alkyl group Chemical group 0.000 claims description 72
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 64
150000001875 compounds Chemical class 0.000 claims description 55
-1 nitro, carboxyl Chemical group 0.000 claims description 53
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
239000001257 hydrogen Substances 0.000 claims description 35
229910052739 hydrogen Inorganic materials 0.000 claims description 35
239000000460 chlorine Substances 0.000 claims description 33
229910052801 chlorine Inorganic materials 0.000 claims description 32
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 30
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 30
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 30
229910052794 bromium Inorganic materials 0.000 claims description 30
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 29
125000002252 acyl group Chemical group 0.000 claims description 28
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
150000002431 hydrogen Chemical class 0.000 claims description 25
125000001424 substituent group Chemical group 0.000 claims description 24
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
239000011737 fluorine Substances 0.000 claims description 23
229910052731 fluorine Inorganic materials 0.000 claims description 23
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
125000004076 pyridyl group Chemical group 0.000 claims description 21
229910052736 halogen Inorganic materials 0.000 claims description 18
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 17
150000002367 halogens Chemical class 0.000 claims description 17
125000003545 alkoxy group Chemical group 0.000 claims description 16
125000004093 cyano group Chemical group *C#N 0.000 claims description 16
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
125000001544 thienyl group Chemical group 0.000 claims description 15
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 14
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
125000003342 alkenyl group Chemical group 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 11
229910052717 sulfur Inorganic materials 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
125000001153 fluoro group Chemical group F* 0.000 claims description 10
125000002541 furyl group Chemical group 0.000 claims description 9
229910052760 oxygen Inorganic materials 0.000 claims description 9
239000001301 oxygen Substances 0.000 claims description 9
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 9
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000000623 heterocyclic group Chemical group 0.000 claims description 8
125000002883 imidazolyl group Chemical group 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
125000000335 thiazolyl group Chemical group 0.000 claims description 7
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
125000004434 sulfur atom Chemical group 0.000 claims description 6
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
230000006020 chronic inflammation Effects 0.000 claims description 5
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 5
125000005842 heteroatom Chemical group 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
125000005493 quinolyl group Chemical group 0.000 claims description 5
125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 4
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
JVJQPDTXIALXOG-UHFFFAOYSA-N nitryl fluoride Chemical compound [O-][N+](F)=O JVJQPDTXIALXOG-UHFFFAOYSA-N 0.000 claims description 4
KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
230000008578 acute process Effects 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
125000002757 morpholinyl group Chemical group 0.000 claims description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
125000003277 amino group Chemical group 0.000 claims description 2
SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
239000012442 inert solvent Substances 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
125000003386 piperidinyl group Chemical group 0.000 claims description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
239000002158 endotoxin Substances 0.000 description 14
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
229920006008 lipopolysaccharide Polymers 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
235000019439 ethyl acetate Nutrition 0.000 description 8
210000001616 monocyte Anatomy 0.000 description 8
210000000224 granular leucocyte Anatomy 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 6
229940095074 cyclic amp Drugs 0.000 description 6
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 5
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
239000002585 base Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
102000003390 tumor necrosis factor Human genes 0.000 description 5
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
102000019197 Superoxide Dismutase Human genes 0.000 description 3
108010012715 Superoxide dismutase Proteins 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000031261 interleukin-10 production Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
210000001539 phagocyte Anatomy 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
WZUODJNEIXSNEU-UHFFFAOYSA-N 2-Hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1 WZUODJNEIXSNEU-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
FDRYADKKCJHYJU-UHFFFAOYSA-N 2-hydroxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C(O)=C1 FDRYADKKCJHYJU-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000018832 Cytochromes Human genes 0.000 description 2
108010052832 Cytochromes Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000038016 acute inflammation Diseases 0.000 description 2
230000006022 acute inflammation Effects 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
231100000225 lethality Toxicity 0.000 description 2
239000002609 medium Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000035939 shock Effects 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000006433 tumor necrosis factor production Effects 0.000 description 2
AEZPKHGVEGZXGF-UHFFFAOYSA-N (3-amino-6-methoxy-1-benzofuran-2-yl)-(3-nitrophenyl)methanone Chemical compound O1C2=CC(OC)=CC=C2C(N)=C1C(=O)C1=CC=CC([N+]([O-])=O)=C1 AEZPKHGVEGZXGF-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
125000004747 1,1-dimethylethoxycarbonyl group Chemical group CC(C)(OC(=O)*)C 0.000 description 1
FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
YDZYREHHCRHTRZ-UHFFFAOYSA-N 4-methylbenzenesulfonyl iodide Chemical compound CC1=CC=C(S(I)(=O)=O)C=C1 YDZYREHHCRHTRZ-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000021435 AMP binding proteins Human genes 0.000 description 1
108091011073 AMP binding proteins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
208000031814 IgA Vasculitis Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
102000004722 NADPH Oxidases Human genes 0.000 description 1
108010002998 NADPH Oxidases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
239000004280 Sodium formate Substances 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
229920000392 Zymosan Polymers 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
229910001863 barium hydroxide Inorganic materials 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000019664 bone resorption disease Diseases 0.000 description 1
239000012267 brine Substances 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229950005499 carbon tetrachloride Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
125000005390 cinnolyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
229960002887 deanol Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000012973 diazabicyclooctane Substances 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
239000000469 ethanolic extract Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000005826 halohydrocarbons Chemical class 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
239000005457 ice water Substances 0.000 description 1
208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
125000005968 oxazolinyl group Chemical group 0.000 description 1
150000002927 oxygen compounds Chemical class 0.000 description 1
125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000005544 phthalimido group Chemical group 0.000 description 1
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002265 prevention Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical class [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
235000019254 sodium formate Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
229910000166 zirconium phosphate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Cosmetics (AREA)

NO19960884A 1995-03-06 1996-03-05 N-(3-benzofuranyl)urea-derivater, farmasöytiske sammensetninger og anvendelse derav, samt fremgangsmåte NO313672B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9504460.8A GB9504460D0 (en)	1995-03-06	1995-03-06	N-(3-Benzofuranyl)urea-derivatives

Publications (3)

Publication Number	Publication Date
NO960884D0 NO960884D0 (no)	1996-03-05
NO960884L NO960884L (no)	1996-09-09
NO313672B1 true NO313672B1 (no)	2002-11-11

Family

ID=10770709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19960884A NO313672B1 (no)	1995-03-06	1996-03-05	N-(3-benzofuranyl)urea-derivater, farmasöytiske sammensetninger og anvendelse derav, samt fremgangsmåte

Country Status (42)

Country	Link
US (2)	US6399657B1 (fr)
EP (1)	EP0731099B1 (fr)
JP (1)	JP3204901B2 (fr)
KR (2)	KR100405579B1 (fr)
CN (2)	CN1134419A (fr)
AR (1)	AR002710A1 (fr)
AT (1)	ATE193704T1 (fr)
BG (2)	BG62732B1 (fr)
BR (1)	BR9600930A (fr)
CA (1)	CA2170824A1 (fr)
CO (1)	CO4370145A1 (fr)
CZ (1)	CZ66796A3 (fr)
DE (1)	DE69608721T2 (fr)
DK (1)	DK0731099T3 (fr)
DZ (1)	DZ1998A1 (fr)
EE (1)	EE03921B1 (fr)
ES (1)	ES2147320T3 (fr)
FI (1)	FI960998A (fr)
GB (1)	GB9504460D0 (fr)
GR (1)	GR3034240T3 (fr)
HK (1)	HK1013285A1 (fr)
HR (1)	HRP960071B1 (fr)
HU (1)	HU222282B1 (fr)
IL (1)	IL117349A (fr)
MA (1)	MA23815A1 (fr)
MY (1)	MY117526A (fr)
NO (1)	NO313672B1 (fr)
NZ (1)	NZ286107A (fr)
PE (1)	PE43597A1 (fr)
PL (1)	PL189206B1 (fr)
PT (1)	PT731099E (fr)
RO (1)	RO116622B1 (fr)
RU (1)	RU2162845C2 (fr)
SI (1)	SI0731099T1 (fr)
SK (1)	SK281817B6 (fr)
SV (1)	SV1996000015A (fr)
TN (1)	TNSN96035A1 (fr)
TR (1)	TR199600177A2 (fr)
TW (1)	TW336934B (fr)
UA (1)	UA46714C2 (fr)
YU (1)	YU49359B (fr)
ZA (1)	ZA961774B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9312853D0 (en)	1993-06-22	1993-08-04	Euro Celtique Sa	Chemical compounds
US5922751A (en)	1994-06-24	1999-07-13	Euro-Celtique, S.A.	Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en)	1994-06-24	1997-01-07	Euro-Celtique, S.A.	Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9504460D0 (en) *	1995-03-06	1995-04-26	Bayer Ag	N-(3-Benzofuranyl)urea-derivatives
US6166041A (en)	1995-10-11	2000-12-26	Euro-Celtique, S.A.	2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
GB9525262D0 (en) *	1995-12-11	1996-02-07	Bayer Ag	Heterocyclylcarbonyl substituted benzofuranyl-ureas
US6075016A (en)	1996-04-10	2000-06-13	Euro-Celtique S.A.	6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9614718D0 (en)	1996-07-12	1996-09-04	Bayer Ag	3-ureido-pyridofurans and -pyridothiophenes
JPH10168095A (ja)	1996-12-10	1998-06-23	Cci Corp	炎症性腸疾患予防および治療剤
WO2000027802A1 (fr) *	1998-11-12	2000-05-18	Ariad Pharmaceuticals, Inc.	Inhibiteurs de transduction de signaux bicycliques, compositions les contenant et utilisation de ces dernieres
GB2350109A (en) *	1999-05-17	2000-11-22	Bayer Ag	Pharmaceutically active benzofuranyl sulfonates
GB2350112A (en) *	1999-05-17	2000-11-22	Bayer Ag	Pharmaceutically active cycloalkyl ketones
GB2350110A (en) *	1999-05-17	2000-11-22	Bayer Ag	Pharmaceutically active benzofurans
GB2350111A (en) *	1999-05-17	2000-11-22	Bayer Ag	Oligohydroxyl substituted 3-urea-benzofuran and pyridofuran derivatives
US7144885B2 (en)	2002-02-22	2006-12-05	Bayer Pharmaceuticals Corporation	Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
MXPA04007391A (es) *	2002-02-22	2004-10-11	Bayer Pharmaceuticals Corp	Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
JP4206382B2 (ja) *	2002-11-19	2009-01-07	アキリオンファーマシューティカルズ，インコーポレーテッド	置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
US7186725B2 (en)	2003-01-03	2007-03-06	Genzyme Corporation	Anti-inflammatory compositions and methods
TW200528459A (en) *	2004-01-06	2005-09-01	Achillion Pharmaceuticals Inc	Azabenzofuran substituted thioureas; inhibitors of viral replication
TW200600492A (en) *	2004-05-18	2006-01-01	Achillion Pharmaceuticals Inc	Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006137350A1 (fr) *	2005-06-22	2006-12-28	Kissei Pharmaceutical Co., Ltd.	Nouveau dérivé de furopyridine, composition pharmaceutique comprenant le dérivé et utilisation du dérivé ou de la composition
ME01901B (me)	2006-07-05	2014-12-20	Astrazeneca Ab	Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
US20140057978A1 (en)	2011-03-17	2014-02-27	Algiax Pharmaceuticals Gmbh	Novel use of benzofuranylsulfonates
WO2013156232A1 (fr) *	2012-04-16	2013-10-24	Algiax Pharmaceuticals Gmbh	Utilisation de benzofuranylsulfonates dans la douleur neuropathique
CA2941782C (fr)	2014-03-18	2022-08-23	Algiax Pharmaceuticals Gmbh	Derives de 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide
EP3165224A1 (fr)	2015-11-09	2017-05-10	Albert-Ludwigs-Universität Freiburg	Utilisation d'inhibiteurs de pde4 pour la prophylaxie et/ou la thérapie de la dyslipoproteinémie et des troubles apparentés
WO2017089347A1 (fr)	2015-11-25	2017-06-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
JP6788966B2 (ja) *	2015-12-24	2020-11-25	丸善製薬株式会社	化粧料
EP4020024A1 (fr)	2020-12-22	2022-06-29	Paul Scherrer Institut	Procédé de production d'optique à rapport de forme élevé en forme de ventilateur

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA824343B (en) *	1981-07-01	1983-04-27	Upjohn Co	Pyridinyl- and imidazolyl-benzofurane and benzothiophenes
US4933351A (en) *	1983-10-31	1990-06-12	Merck Frosst Canada, Inc.	Benzofuran 2-carbox amides useful as inhibitors of leukoriene biosynthesis
US4822803A (en) *	1983-10-31	1989-04-18	Merck Frosst Canada, Inc.	Benzofuran 2-carboxylic acid hydrazides useful as inhibitors of leukotriene biosynthesis
US4663347A (en)	1983-10-31	1987-05-05	Merck Frosst Canada, Inc.	Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
EP0146243A1 (fr) *	1983-10-31	1985-06-26	Merck Frosst Canada Inc.	Inhibiteurs de la lipoxygénase
US5087638A (en) *	1984-06-20	1992-02-11	Merck Frosst Canada, Inc.	Benzofuran derivatives
GB9200623D0 (en) *	1992-01-13	1992-03-11	Bayer Ag	Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
GB9309324D0 (en) *	1993-05-06	1993-06-16	Bayer Ag	Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
GB9504460D0 (en) *	1995-03-06	1995-04-26	Bayer Ag	N-(3-Benzofuranyl)urea-derivatives

1995
- 1995-03-06 GB GBGB9504460.8A patent/GB9504460D0/en active Pending
1996
- 1996-02-13 HR HR960071A patent/HRP960071B1/xx not_active IP Right Cessation
- 1996-02-22 ES ES96102650T patent/ES2147320T3/es not_active Expired - Lifetime
- 1996-02-22 DK DK96102650T patent/DK0731099T3/da active
- 1996-02-22 DE DE69608721T patent/DE69608721T2/de not_active Expired - Fee Related
- 1996-02-22 PT PT96102650T patent/PT731099E/pt unknown
- 1996-02-22 AT AT96102650T patent/ATE193704T1/de not_active IP Right Cessation
- 1996-02-22 EP EP96102650A patent/EP0731099B1/fr not_active Expired - Lifetime
- 1996-02-22 SI SI9630186T patent/SI0731099T1/xx unknown
- 1996-02-28 AR ARP960101567A patent/AR002710A1/es unknown
- 1996-02-29 RO RO96-00425A patent/RO116622B1/ro unknown
- 1996-03-01 MA MA24172A patent/MA23815A1/fr unknown
- 1996-03-01 NZ NZ286107A patent/NZ286107A/en unknown
- 1996-03-01 CA CA002170824A patent/CA2170824A1/fr not_active Abandoned
- 1996-03-04 BG BG100396A patent/BG62732B1/bg unknown
- 1996-03-04 FI FI960998A patent/FI960998A/fi not_active IP Right Cessation
- 1996-03-04 BG BG100396A patent/BG100396A/bg unknown
- 1996-03-04 TN TNTNSN96035A patent/TNSN96035A1/fr unknown
- 1996-03-04 IL IL11734996A patent/IL117349A/en not_active IP Right Cessation
- 1996-03-04 PL PL96313070A patent/PL189206B1/pl not_active IP Right Cessation
- 1996-03-05 YU YU13396A patent/YU49359B/sh unknown
- 1996-03-05 KR KR1019960005676A patent/KR100405579B1/ko not_active IP Right Cessation
- 1996-03-05 HU HU9600549A patent/HU222282B1/hu not_active IP Right Cessation
- 1996-03-05 JP JP07308496A patent/JP3204901B2/ja not_active Expired - Fee Related
- 1996-03-05 MY MYPI96000815A patent/MY117526A/en unknown
- 1996-03-05 DZ DZ960039A patent/DZ1998A1/fr active
- 1996-03-05 UA UA96030864A patent/UA46714C2/uk unknown
- 1996-03-05 CZ CZ96667A patent/CZ66796A3/cs unknown
- 1996-03-05 ZA ZA961774A patent/ZA961774B/xx unknown
- 1996-03-05 SK SK297-96A patent/SK281817B6/sk unknown
- 1996-03-05 EE EE9600030A patent/EE03921B1/xx not_active IP Right Cessation
- 1996-03-05 RU RU96104360/04A patent/RU2162845C2/ru not_active IP Right Cessation
- 1996-03-05 TR TR96/00177A patent/TR199600177A2/xx unknown
- 1996-03-05 TW TW085102648A patent/TW336934B/zh active
- 1996-03-05 NO NO19960884A patent/NO313672B1/no unknown
- 1996-03-06 SV SV1996000015A patent/SV1996000015A/es unknown
- 1996-03-06 BR BR9600930A patent/BR9600930A/pt not_active Application Discontinuation
- 1996-03-06 CO CO96010870A patent/CO4370145A1/es unknown
- 1996-03-06 PE PE1996000153A patent/PE43597A1/es not_active Application Discontinuation
- 1996-03-06 CN CN96103073A patent/CN1134419A/zh active Pending
- 1996-03-06 CN CNB011033924A patent/CN1176651C/zh not_active Expired - Fee Related
1998
- 1998-12-22 HK HK98114554A patent/HK1013285A1/xx not_active IP Right Cessation
1999
- 1999-05-21 US US09/316,536 patent/US6399657B1/en not_active Expired - Fee Related
2000
- 2000-08-23 GR GR20000401927T patent/GR3034240T3/el not_active IP Right Cessation
2002
- 2002-05-24 US US10/154,743 patent/US6677372B2/en not_active Expired - Fee Related
2003
- 2003-06-24 KR KR1020030040949A patent/KR100438633B1/ko not_active IP Right Cessation

Also Published As

Publication number	Publication date
US6677372B2 (en)	2004-01-13
UA46714C2 (uk)	2002-06-17
HRP960071B1 (en)	2001-04-30
ATE193704T1 (de)	2000-06-15
RU2162845C2 (ru)	2001-02-10
BG62732B1 (bg)	2000-06-30
SV1996000015A (es)	1997-02-17
DK0731099T3 (da)	2000-09-25
SI0731099T1 (en)	2000-08-31
HU222282B1 (hu)	2003-05-28
ZA961774B (en)	1996-09-17
AU4582896A (en)	1996-09-19
HU9600549D0 (en)	1996-04-29
FI960998A0 (fi)	1996-03-04
CN1313284A (zh)	2001-09-19
TR199600177A2 (tr)	1996-10-21
EE9600030A (et)	1996-10-15
KR100405579B1 (ko)	2004-03-19
CA2170824A1 (fr)	1996-09-07
YU49359B (sh)	2005-09-19
HRP960071A2 (en)	1997-12-31
RO116622B1 (ro)	2001-04-30
KR960034194A (ko)	1996-10-22
CN1176651C (zh)	2004-11-24
HUP9600549A3 (en)	1998-04-28
CZ66796A3 (en)	1996-09-11
ES2147320T3 (es)	2000-09-01
FI960998A (fi)	1996-09-07
DE69608721T2 (de)	2000-10-05
MY117526A (en)	2004-07-31
BR9600930A (pt)	1997-12-30
EP0731099B1 (fr)	2000-06-07
PT731099E (pt)	2000-11-30
PL313070A1 (en)	1996-09-16
PL189206B1 (pl)	2005-07-29
SK281817B6 (sk)	2001-08-06
HK1013285A1 (en)	1999-08-20
EP0731099A1 (fr)	1996-09-11
JPH08253466A (ja)	1996-10-01
DZ1998A1 (fr)	2002-07-20
BG100396A (bg)	1996-12-31
CN1134419A (zh)	1996-10-30
TW336934B (en)	1998-07-21
AU705667B2 (en)	1999-05-27
HUP9600549A2 (en)	1997-07-28
DE69608721D1 (de)	2000-07-13
KR100438633B1 (ko)	2004-07-02
YU13396A (sh)	1999-06-15
MA23815A1 (fr)	1996-10-01
TNSN96035A1 (fr)	2005-03-15
US6399657B1 (en)	2002-06-04
IL117349A (en)	2002-09-12
NZ286107A (en)	1998-08-26
PE43597A1 (es)	1997-12-26
AR002710A1 (es)	1998-04-29
CO4370145A1 (es)	1996-10-07
NO960884L (no)	1996-09-09
JP3204901B2 (ja)	2001-09-04
GB9504460D0 (en)	1995-04-26
EE03921B1 (et)	2002-12-16
GR3034240T3 (en)	2000-12-29
NO960884D0 (no)	1996-03-05
SK29796A3 (en)	1996-10-02
IL117349A0 (en)	1996-07-23
US20030109578A1 (en)	2003-06-12

Publication	Publication Date	Title
NO313672B1 (no)	2002-11-11	N-(3-benzofuranyl)urea-derivater, farmasöytiske sammensetninger og anvendelse derav, samt fremgangsmåte
US6169092B1 (en)	2001-01-02	3-Ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes
EP0779291B1 (fr)	2001-10-10	Benzofuranyl-urée substitué par un héterocycliquecarbonyle
EP0685475B1 (fr)	1999-01-13	Dérivés de aminobenzofuryle et -thienyle
EP0623607B1 (fr)	1998-07-15	Dérivés d'acide benzofurane- et thiophène alcanoique
EP0685474A1 (fr)	1995-12-06	Dérivés de oxalylamino-benzofuranne et -benzothienyle
EP0296879A1 (fr)	1988-12-28	Sulfonamides aromatiques, substituées, comme agents anti-glaucomes
SK160498A3 (en)	1999-06-11	Benzofuran carboxamides and their therapeutic use
KR19990071894A (ko)	1999-09-27	벤조퓨란 카르복사미드 및 술폰아미드
JP2004523475A (ja)	2004-08-05	タンパク質Ｊｕｎキナーゼのインヒビターとしての医薬的活性ベンズスルホンアミド誘導体
JP2004510772A (ja)	2004-04-08	タンパク質Ｊｕｎ−キナーゼのインヒビターとしての医薬的活性親水性スルホンアミド誘導体
US6610687B1 (en)	2003-08-26	Benzofuranylsulfonates
JPH0673012A (ja)	1994-03-15	４−イミノキノリン、その製法およびその使用
GB2350110A (en)	2000-11-22	Pharmaceutically active benzofurans
GB2350112A (en)	2000-11-22	Pharmaceutically active cycloalkyl ketones
WO2000069844A1 (fr)	2000-11-23	Derives de pyridofuranyluree et de benzofuran-3-yle a substitution oligohydroxyle convenant comme inhibiteurs des phosphodiesterases iv
JP5640256B2 (ja)	2014-12-17	ＰＰＡＲγアゴニスト